Patents by Inventor Qi Chao

Qi Chao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230089374
    Abstract: Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme glycolate oxidase (GO). Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.
    Type: Application
    Filed: May 23, 2022
    Publication date: March 23, 2023
    Applicant: BIOMARIN PHARMACEUTICAL INC.
    Inventors: Bing WANG, Qi CHAO
  • Publication number: 20230079913
    Abstract: Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme glycolate oxidase (GO). Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.
    Type: Application
    Filed: May 23, 2022
    Publication date: March 16, 2023
    Applicant: BIOMARIN PHARMACEUTICAL INC.
    Inventors: Bing WANG, Qi CHAO
  • Patent number: 11384055
    Abstract: Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme glycolate oxidase (GO). Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.
    Type: Grant
    Filed: December 28, 2018
    Date of Patent: July 12, 2022
    Assignee: BIOMARIN PHARMACEUTICAL INC.
    Inventors: Bing Wang, Qi Chao
  • Publication number: 20210171474
    Abstract: Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme glycolate oxidase (GO). Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.
    Type: Application
    Filed: December 28, 2018
    Publication date: June 10, 2021
    Applicant: BIOMARIN PHARMACEUTICAL INC.
    Inventors: Bing Wang, Qi Chao
  • Patent number: 10053430
    Abstract: Compounds, compositions and methods are provided for modulating the activity of RAF kinases, including BRAF kinase and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by RAF kinases.
    Type: Grant
    Filed: June 28, 2017
    Date of Patent: August 21, 2018
    Assignee: AMBIT BIOSCIENCES CORP.
    Inventors: Sunny Abraham, Shripad S. Bhagwat, Brian T. Campbell, Qi Chao, Raffaella Faraoni, Mark W. Holladay, Andiliy G. Lai, Martin W. Rowbottom, Eduardo Setti, Kelly G. Sprankle
  • Patent number: 9975880
    Abstract: Imidazolidine-2,4-dione derivatives of formula (I): These compounds have anti-proliferative activity and are useful for treating pathological states and diseases linked to an abnormal cell proliferation, such as cancer.
    Type: Grant
    Filed: December 31, 2013
    Date of Patent: May 22, 2018
    Assignee: IPSEN PHARMA S.A.S.
    Inventors: Serge Auvin, Christophe Lanco, Oliver Dutruel, Qi Chao, Kaichun Gu
  • Publication number: 20170348320
    Abstract: Compounds, compositions and methods are provided for modulating the activity of receptor kinases and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by receptor kinases.
    Type: Application
    Filed: June 26, 2017
    Publication date: December 7, 2017
    Inventors: Shripad Bhagwat, Qi Chao, Robert M. Grotzfeld, Hitesh K. Patel, Kelly G. Sprankle
  • Publication number: 20170298029
    Abstract: Compounds, compositions and methods are provided for modulating the activity of RAF kinases, including BRAF kinase and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by RAF kinases.
    Type: Application
    Filed: June 28, 2017
    Publication date: October 19, 2017
    Applicant: AMBIT BIOSCIENCES CORPORATION
    Inventors: Sunny ABRAHAM, Shripad S. BHAGWAT, Brian T. CAMPBELL, Qi CHAO, Raffaella FARAONI, Mark W. HOLLADAY, Andiliy G. LAI, Martin W. ROWBOTTOM, Eduardo SETTI, Kelly G. SPRANKLE
  • Patent number: 9730937
    Abstract: Compounds, compositions and methods are provided for modulating the activity of RAF kinases, including BRAF kinase and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by RAF kinases.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: August 15, 2017
    Assignee: AMBIT BIOSCIENCES CORPORATION
    Inventors: Sunny Abraham, Shripad S. Bhagwat, Brian T. Campbell, Qi Chao, Raffaella Faraoni, Mark W. Holladay, Andiliy G. Lai, Martin W. Rowbottom, Eduardo Setti, Kelly G. Sprankle
  • Patent number: 9682941
    Abstract: The present invention relates to new biphenyl derivatives of formula These compounds acting as aromatase and sulfatase inhibitors, they are particularly useful for treating pathological conditions or diseases in which aromatase and sulfatase are involved. Moreover, the present invention provides processes for the preparation of these compounds. The invention also relates to pharmaceutical compositions containing said products and their use for the preparation of a medicament, in particular for the treatment of diseases characterized by aromatase and sulfatase activity such as hormone-dependent cancers.
    Type: Grant
    Filed: December 31, 2013
    Date of Patent: June 20, 2017
    Assignee: ESTRYX PHARMA LIMITED
    Inventors: Serge Auvin, Olivier Lavergne, Qi Chao, Yufeng Chen
  • Patent number: 9676752
    Abstract: Imidazolidine-2,4-dione derivatives of formula (I): The compounds have anti-proliferative activity and are useful for treating pathological states and diseases linked to an abnormal cell proliferation such as cancer.
    Type: Grant
    Filed: December 31, 2013
    Date of Patent: June 13, 2017
    Assignee: IPSEN PHARMA S.A.S.
    Inventors: Serge Auvin, Christophe Lanco, Qi Chao, Kaichun Gu
  • Publication number: 20170001964
    Abstract: The present invention relates to new biphenyl derivatives of formula These compounds acting as aromatase and sulfatase inhibitors, they are particularly useful for treating pathological conditions or diseases in which aromatase and sulfatase are involved. Moreover, the present invention provides processes for the preparation of these compounds. The invention also relates to pharmaceutical compositions containing said products and their use for the preparation of a medicament, in particular for the treatment of diseases characterized by aromatase and sulfatase activity such as hormone-dependent cancers.
    Type: Application
    Filed: December 31, 2013
    Publication date: January 5, 2017
    Inventors: Serge AUVIN, Olivier LAVERGNE, Qi CHAO, Yufeng CHEN
  • Publication number: 20160318902
    Abstract: Imidazolidine-2,4-dione derivatives of formula (I): The compounds have anti-proliferative activity and are useful for treating pathological states and diseases linked to an abnormal cell proliferation such as cancer.
    Type: Application
    Filed: December 31, 2013
    Publication date: November 3, 2016
    Inventors: Serge AUVIN, Christophe LANCO, Qi CHAO, Kaichun GU
  • Publication number: 20160318908
    Abstract: Imidazolidine-2,4-dione derivatives of formula (I): These compounds have anti-proliferative activity and are useful for treating pathological states and diseases linked to an abnormal cell proliferation, such as cancer.
    Type: Application
    Filed: December 31, 2013
    Publication date: November 3, 2016
    Inventors: Serge AUVIN, Christophe LANCO, Oliver DUTRUEL, Qi CHAO, Kaichun GU
  • Publication number: 20160199375
    Abstract: Compounds, compositions and methods are provided for modulating the activity of RAF kinases, including BRAF kinase and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by RAF kinases.
    Type: Application
    Filed: March 18, 2016
    Publication date: July 14, 2016
    Inventors: Sunny Abraham, Shripad S. Bhagwat, Brian T. Campbell, Qi Chao, Raffaella Faraoni, Mark W. Holladay, Andiliy G. Lai, Martin W. Rowbottom, Eduardo Setti, Kelly G. Sprankle
  • Patent number: 9320739
    Abstract: Compositions of 1-(3-((6,7-dimethoxyquinazolin-4-yl)oxy)phenyl)-3-(5-(1,1,1, -trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea are provided for modulating the activity of RAF kinases, including BRAF kinase and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by RAF kinases.
    Type: Grant
    Filed: January 26, 2015
    Date of Patent: April 26, 2016
    Assignee: Ambit Biosciences Corporation
    Inventors: Sunny Abraham, Shripad S. Bhagwat, Brian T. Campbell, Qi Chao, Raffaella Faraoni, Mark W. Holladay, Andiliy G. Lai, Martin W. Rowbottom, Eduardo Setti, Kelly G. Sprankle
  • Patent number: 9308207
    Abstract: Provided herein are quinazoline compounds of formula (I): The compounds are useful for treatment of JAK kinase mediated diseases, including JAK2 kinase-, JAK3 kinase- or TYK2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.
    Type: Grant
    Filed: December 2, 2014
    Date of Patent: April 12, 2016
    Assignee: Ambit Biosciences Corp.
    Inventors: Sunny Abraham, Qi Chao, Michael J. Hadd, Mark W. Holladay, Gang Liu, Eduardo Setti
  • Patent number: 9259271
    Abstract: A medical insertion device which may be used with or installed within an imaging system, such as magnetic resonance imaging (MRI). The medical insertion device can generally be used to retain, position and effect insertion of a medical instrument, for example a biopsy device or an ablation treatment device. The device can generally provide linear and/or angular degrees of freedom for positioning of the medical instrument prior to an insertion of the medical instrument. The medical insertion device includes a mounting arm, an interface connected to the mounting arm for interfacing with a medical instrument, a mechanism for movement of the medical instrument or a part of the medical instrument in an insertion direction, a carriage connected to a distal end of the mounting arm, and a pivot connection between the carriage and the distal end of the mounting arm to permit pitch or yaw of the mounting arm.
    Type: Grant
    Filed: November 26, 2010
    Date of Patent: February 16, 2016
    Inventors: Mehran Anvari, Lianne Stefurak, Tim Reedman, Timothy Scott Fielding, Michael Richard Max Schmidt, Kevin John Randall, Julian Dobranowski, Colm Boylan, Lawrence Qi Chao Lee, Kevin Warren Morency
  • Publication number: 20150246042
    Abstract: Compounds, compositions and methods are provided for modulating the activity of RAF kinases, including BRAF kinase and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by RAF kinases.
    Type: Application
    Filed: January 26, 2015
    Publication date: September 3, 2015
    Applicant: AMBIT BIOSCIENCES CORPORATION
    Inventors: Sunny Abraham, Shripad S. Bhagwat, Brian T. Campbell, Qi Chao, Raffaella Faraoni, Mark W. Holladay, Andiliy G. Lai, Martin W. Rowbottom, Eduardo Setti, Kelly G. Sprankle
  • Publication number: 20150150874
    Abstract: Provided herein are quinazoline compounds for treatment of JAK kinase mediated diseases, including JAK2 kinase-, JAK3 kinase- or TYK2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.
    Type: Application
    Filed: December 2, 2014
    Publication date: June 4, 2015
    Applicant: Ambit Biosciences Corp.
    Inventors: Sunny Abraham, Qi Chao, Michael J. Hadd, Mark W. Holladay, Gang Liu, Eduardo Setti